Perrigo Company plc PRGO reported adjusted earnings of 86 cents per share in the fourth quarter of 2023, surpassing the Zacks Consensus Estimate of 83 cents. Earnings saw a 14.7% surge compared to the previous year, largely due to prudent cost management by the company.
Net sales inched up by 0.1% year over year to $1.16 billion, falling short of the Zacks Consensus Estimate of $1.19 billion. Despite this, the uptick was supported by the acquisition of the U.S. & Canadian Good Start infant formula brand and favorable currency movements, although it was partially offset by a decline in organic net sales.
Sales for the quarter witnessed a 1.4% rise driven by favorable currency movements, but excluding foreign currency translation, sales sagged by 1.2%. Organically, sales dipped by 0.6% compared to the previous year.
The Segmented Story
Perrigo operates under the Consumer Self Care Americas (“CSCA”) and Consumer Self Care International (“CSCI”) segments.
CSCA: The segment’s net sales for the quarter settled at $744.4 million, marking a 2.8% decline year over year. The drop was primarily due to strategic SKU prioritization actions aimed at enhancing margins as part of the Supply Chain Reinvention Program initiated in 2022 and weaker net sales of Nutrition and Oral Care products in the U.S.
CSCI: The segment reported net sales of $412.6 million, reflecting a 5.9% uptick from the previous year. Revenue growth was fueled by favorable currency movements and increased net sales of Pain & Sleep-Aids and VMS products. Adjusted for currency fluctuations, sales were up 1.8% year over year. On an organic basis, sales showed a robust increase of 2.9%.
The Full-Year Picture
For the full year of 2023, Perrigo reported revenues of $4.66 billion, marking a 4.6% climb year over year. Net sales also saw a 1.7% organic increase. Adjusted earnings per share for the year stood at $2.58, reflecting a 24.6% surge compared to the previous year.
The Road Ahead in 2024
Perrigo has issued a fresh financial outlook for 2024, anticipating flat year-over-year growth in total net sales. Adjusted earnings per share are forecasted to be in the range of $2.50 to $2.65. However, the Zacks Consensus Estimate paints a brighter picture with total revenues and earnings projected at $4.91 billion and $2.94 per share, respectively.
Despite a pre-market stumble on Feb 27, with shares declining by 10.4%, Perrigo remains steady year-to-date, mirroring the industry’s 4.7% rise.
Forecasts hint at an adjusted tax rate of approximately 20.5% for the year, with an estimated $180 million in interest expenses. The company seems poised for a challenging yet promising year ahead.
Embracing Change: Project Energize
Embarking from the first quarter of 2024, Perrigo has kickstarted Project Energize, a three-year initiative aimed at enhancing organizational flexibility and addressing the implications of its intended expansion and enhancement of the infant formula business.
Project Energize, a blend of investment and efficiency measures, seeks to streamline costs while reinvesting back into key areas of the company’s operations.
As part of the restructuring drive under the project, Perrigo plans to reduce approximately 6% of its current workforce. Management anticipates achieving annualized pre-tax savings ranging from $140 million to $170 million by 2026. Out of the total savings, a chunk will be reinvested, totaling an estimated $40 million to $60 million, to expand its blended-brand business model.
The restructuring process is expected to incur costs of $140 million to $160 million by 2026, including investments ranging from $20 million to $40 million. While challenging, these strategic shifts are deemed essential for the company’s future growth and adaptability.
